TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2890150

Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg at night)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg at night)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All drugs (Famotidine and Ranitidine)
Number of subjects: 9
Study: 30587165

Group type: EXPERIMENTAL
Intervention: Simvastatin administration
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 106
Study: 27841968

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) applied at 10 points through the surgical scar in three sessions.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (disabled laser) applied at the same points and sessions as LLLT.
Number of subjects: 85
Study: 23458566

Group type: EXPERIMENTAL
Intervention: Nonremoval of abutments during surgery (one abutment at one time test protocol)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (removal of abutments and standard prosthetic protocol)
Number of subjects: 68
Study: 22534479

Group type: EXPERIMENTAL
Intervention: MARS treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PE+MARS treatment
Number of subjects: 120
Study: 20862935

Group type: EXPERIMENTAL
Intervention: Electroacupuncture on Quchi (LI 11) and Taichong (LR 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication (Captopril)
Number of subjects: 60
Study: 18187817

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg twice daily for the first month and 200 mg once daily for the next month (total duration 2 months)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Chloroquine 250 mg twice daily for the first month and 250 mg once daily for the next month (total duration 2 months)
Number of subjects: 117
Study: 15679621

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12940470

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years Program (PDFY)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 429
Study: 10485271

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered 2 h before cyclophosphamide (CP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha) administered 24 h after cyclophosphamide (CP)
Number of subjects: 10
Study: 7815355

Group type: COMPARATOR
Intervention: LTB4 (3 ng/site)
Number of subjects: 22

Group type: COMPARATOR
Intervention: LTB4 (10 ng/site)
Number of subjects: 22

Group type: COMPARATOR
Intervention: LTB4 (30 ng/site)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 10(-9) mol/site)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Naproxen (oral)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tenidap (oral)
Number of subjects: 22
Study: 1657084

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7104466

Group type: EXPERIMENTAL
Intervention: 50 mg dose of chlorothiazide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg dose of chlorothiazide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 250 mg dose of chlorothiazide
Number of subjects: 8
Study: 31801510

Group type: EXPERIMENTAL
Intervention: Non-closed-suction drain (non-CSD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Closed-suction drain (CSD)
Number of subjects: 32
Study: 29030775

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for three cycles of 21 days
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no prednisolone treatment)
Number of subjects: 241
Study: 24755773

Group type: EXPERIMENTAL
Intervention: Internet-based home training (e-Training)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hippotherapy
Number of subjects: 18
Study: 23560500

Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 22518827

Group type: EXPERIMENTAL
Intervention: 20 mM capsazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mM l‐NAME
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined 10 mM l‐NAME + 20 mM capsazepine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 90% propylene glycol + 10% lactated Ringer (vehicle control)
Number of subjects: 12
Study: 19020863

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (TKA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (TKA)
Number of subjects: 25
Study: 17166313

Group type: EXPERIMENTAL
Intervention: Goal Management Training program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 49
Study: 14985863

Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 68
Study: 12507112

Group type: EXPERIMENTAL
Intervention: High-dose irradiation (mean margin dose of 52.1 Gy)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-dose irradiation (mean margin dose of 41.5 Gy)
Number of subjects: 64
Study: 9578044

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (CBZ) twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate-release carbamazepine (CBZ) four times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 7866473

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2486640

Group type: EXPERIMENTAL
Intervention: Pirprofen (Rengasil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piritramid (Dipidolar)
Number of subjects: 0
Study: 33086

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg at first sign of pain, then 275 mg every six hours as needed)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study: 31026244

Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass Index (LVMI)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Relative Wall Thickness (RWT)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Blood Pressure (DBP and SBP)
Number of subjects: 709
Study: 28549476

Group type: COMPARATOR
Intervention: Education only (non-tailored information only)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Education plus intervention components to enhance motivation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Education plus components to enhance motivation and self‐regulation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Education plus components to enhance motivation, self‐regulation and habit formation
Number of subjects: 192
Study: 24687684

Group type: EXPERIMENTAL
Intervention: Very Low Caloric Diet (VLCD; Ø 600 kcal/day; n = 21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low Caloric Diet (LCD; Ø 1,200 kcal/day; n = 17)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both VLCD and LCD
Number of subjects: 38
Study: 23031209

Group type: EXPERIMENTAL
Intervention: Single-caged (S-33)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-caged (S-42)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group-housed (G)
Number of subjects: 50
Study: 21757247

Group type: EXPERIMENTAL
Intervention: 3D-planned radiotherapy to 60Gy/40 fractions/2.5weeks (CHARTWEL)
Number of subjects: 406

Group type: COMPARATOR
Intervention: 66Gy/33 fractions/6.5weeks (conventional fractionation, CF)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 406

Group type: COMPARATOR
Intervention: CF
Number of subjects: 406
Study: 19225896

Group type: EXPERIMENTAL
Intervention: Decisional balance scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement equivalence/invariance testing
Number of subjects: 0
Study: 17140888

Group type: EXPERIMENTAL
Intervention: uUT‐EGD (5.2-mm-diameter videoscope)
Number of subjects: 120
Study: 15271102

Group type: EXPERIMENTAL
Intervention: Continuous vancomycin infusion (CVI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intermittent vancomycin infusion (IVI)
Number of subjects: 44
Study: 11554706

Group type: EXPERIMENTAL
Intervention: Moisturising cream applied for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control skin
Number of subjects: 13
Study: 9255718

Group type: EXPERIMENTAL
Intervention: Chitosan (30 tablets, 45 mg/tablet, three times a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control treatment (1 week prior to chitosan ingestion)
Number of subjects: 80
Study: 8332651

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg b.d. for two weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matched placebo for two weeks
Number of subjects: 18
Study: 3089439

Group type: EXPERIMENTAL
Intervention: Prednisolone (steroids) for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30119677

Group type: EXPERIMENTAL
Intervention: Robenacoxib 2mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Robenacoxib 6mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Robenacoxib 10mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham control (0mg/kg)
Number of subjects: 32
Study: 26381059

Group type: EXPERIMENTAL
Intervention: PART-O scoring modifications
Number of subjects: 469
Study: 24595149

Group type: EXPERIMENTAL
Intervention: 3 ml (15 mg) 0.5% isobaric levobupivacaine (group L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (group B)
Number of subjects: 100
Study: 21929835

Group type: EXPERIMENTAL
Intervention: EPA (1·67 g EPA + 0·16 g DHA/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DHA (1·55 g DHA + 0·40 g EPA/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: LA (2·2 g/d)
Number of subjects: 50
Study: 20197484

Group type: EXPERIMENTAL
Intervention: Necitumumab 800 mg (flat dosing)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Necitumumab 600 mg or more
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Necitumumab 1000 mg every 2 weeks
Number of subjects: 60
Study: 18806204

Group type: EXPERIMENTAL
Intervention: Topically applied NTG ointment (2%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topically applied NTG ointment (2%) + treadmill ambulation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treadmill ambulation only
Number of subjects: 75
Study: 16894463

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg daily (before July 1999) or Clopidogrel 75 mg daily (after July 1999) for one month
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Killip class >1 on admission
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: SAT presence
Number of subjects: 1548
Study: 12772817

Group type: EXPERIMENTAL
Intervention: Iberogast
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo or cisapride (positive control)
Number of subjects: 592
Study: 11508070

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 78
Study: 8851903

Group type: EXPERIMENTAL
Intervention: Diuretic plus exercise training (D+E)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diuretic (D)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 9
Study: 1626605

Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty
Number of subjects: 161

Group type: COMPARATOR
Intervention: Selective proximal vagotomy alone
Number of subjects: 161
Study: 6647208

Group type: EXPERIMENTAL
Intervention: metoprolol SA (Astra)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: metoprolol SR
Number of subjects: 8

Group type: COMPARATOR
Intervention: conventional metoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: metoprolol (all formulations)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 8
Study: 31203725

Group type: EXPERIMENTAL
Intervention: Nilvadipine treatment
Number of subjects: 58
Study: 30153852

Group type: EXPERIMENTAL
Intervention: Conventional suture-bridge technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Knotless suture-bridge technique
Number of subjects: 100
Study: 27088053

Group type: EXPERIMENTAL
Intervention: Taiji beginner course (Yang-Style Taiji, 2 hours per week, 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (waiting list for the course)
Number of subjects: 70
Study: 25192882

Group type: EXPERIMENTAL
Intervention: Weight management programme including physical exercise and dietary restriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No change comparator (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight management programme
Number of subjects: 0
Study: 22580255

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 274

Group type: COMPARATOR
Intervention: Bare metal stents (Control)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Pooled DES (Paclitaxel and Sirolimus)
Number of subjects: 274
Study: 20646099

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 IU every 3 months (intermittent D(3) group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cholecalciferol 1,000 IU/day (daily D(3) group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17356080

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 3911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3911
Study: 15754269

Group type: EXPERIMENTAL
Intervention: 100 mg of modified‐release aspirin daily
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: 20 mg of simvastatin daily
Number of subjects: 448
Study: 12130413

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 24
Study: 10425885

Group type: EXPERIMENTAL
Intervention: Sodium naproxen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7558992

Group type: EXPERIMENTAL
Intervention: S-R compatibility auditory task
Number of subjects: 10
Study: 1975322

Group type: EXPERIMENTAL
Intervention: Alteplase (tPA)
Number of subjects: 20891

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 20891

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 20891

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 20891
Study: 7023526

Group type: EXPERIMENTAL
Intervention: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by streptomycin and pyrazinamide for the first two months)
Number of subjects: 444

Group type: COMPARATOR
Intervention: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol for the first two months)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by pyrazinamide)
Number of subjects: 444

Group type: COMPARATOR
Intervention: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol)
Number of subjects: 444
Study: 30918097

Group type: EXPERIMENTAL
Intervention: Trofinetide 200 mg/kg bid
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 30096080

Group type: EXPERIMENTAL
Intervention: Fix for Life (F4L) cadavers
Number of subjects: 30

Group type: COMPARATOR
Intervention: SimMan 3G manikin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formalin-fixed cadavers
Number of subjects: 30
Study: 27300156

Group type: EXPERIMENTAL
Intervention: Broad Target Speech Recasts (BTSR)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Contrast treatment
Number of subjects: 51
Study: 25195684

Group type: EXPERIMENTAL
Intervention: Extracorporeal liver support therapy
Number of subjects: 86
Study: 22443312

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 0
Study: 18708192

Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2-lung ventilation (TLV)
Number of subjects: 30
Study: 17767632

Group type: EXPERIMENTAL
Intervention: Tidal volume breathing using an O(2) flow of 9 l x min(‐1) for 3 min (TV x 3 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Four deep breaths within 30 s using an O(2) flow of 15 l x min(‐1) (4 DB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eight deep breaths within 1 min using an O(2) flow of 15 l x min(‐1) (8 DB)
Number of subjects: 20
Study: 15554760

Group type: EXPERIMENTAL
Intervention: Lamotrigine (target dose = 200 mg/day, minimum dose = 100 mg/day)
Number of subjects: 1315
Study: 11592671

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alcohol (.07%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg) under no fatigue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo under fatigue
Number of subjects: 50
Study: 9775640

Group type: EXPERIMENTAL
Intervention: Nightguard vital bleaching using carbamide peroxide (up to 10 percent)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two nightguard bleaching systems
Number of subjects: 12
Study: 7842531

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 gm EPA and 2 gm DHA daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study: 3585610

Group type: EXPERIMENTAL
Intervention: PMN transfusions (15 mL/kg containing 0.5 to 1.0 X 10(9) PMN, one transfusion every 12 hours for a total of five transfusions)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-transfused group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PMN transfusions
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low circulating levels of total hemolytic complement
Number of subjects: 35
Study: 30185930

Group type: EXPERIMENTAL
Intervention: Exogenous cueing with predictable cue-target onset asynchronies (CTOAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous cueing with randomized CTOAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in pupil size to the cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccadic curvature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microsaccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention measures when facilitation is absent
Number of subjects: 0
Study: 28093442

Group type: EXPERIMENTAL
Intervention: CS1002 (Unicough)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Simple Linctus (SL)
Number of subjects: 163
Study: 25162407

Group type: EXPERIMENTAL
Intervention: TENS device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 23
Study: 23358809

Group type: EXPERIMENTAL
Intervention: Coordinated and tailored return-to-work intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional case management
Number of subjects: 168
Study: 21596903

Group type: EXPERIMENTAL
Intervention: Group 3 (culturally targeted materials and telephone‐based motivational interviewing)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Group 1 (standard educational materials)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Group 2 (culturally targeted materials)
Number of subjects: 1021
Study: 18081808

Group type: EXPERIMENTAL
Intervention: Photo-activated disinfection (PAD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Laser alone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dye without laser
Number of subjects: 38
Study: 12752512

Group type: EXPERIMENTAL
Intervention: 16 U of botulinum toxin type A
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 32 U of botulinum toxin type A
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 48 U of botulinum toxin type A
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 59
Study: 10544442

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 148
Study: 7774757

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (4 to 6 g/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-lipase pancreatin (9 g/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Commercial pancreatic enzyme preparations (12 to 24 tablets or 9.0 g)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Omeprazole (50 mg)
Number of subjects: 45
Study: 1964664

Group type: EXPERIMENTAL
Intervention: Subcutaneous fixed doses of a low‐molecular‐weight heparin (CY216; 225 IC anti‐Xa U/kg 12 hourly) for 10 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous adjusted unfractionated heparin (UFH)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (CY216 and UFH)
Number of subjects: 90
Study: 227077

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 130

Group type: COMPARATOR
Intervention: Dimetotiazine
Number of subjects: 130
Study: 31832876

Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine (FT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefuroxime sodium (control)
Number of subjects: 61
Study: 31369185

Group type: EXPERIMENTAL
Intervention: l-carnitine (LC) supplementation 2 g for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29312993

Group type: EXPERIMENTAL
Intervention: Nonsurgical wound pain
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Surgical wound pain
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CO2 removal procedure
Number of subjects: 84